Radiogel™ Precision Radionuclide Therapy™ Receives FDA Breakthrough Device Designation
December 20, 2023 10:08 ET
|
Vivos Inc.
Richland WA, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that the Food and Drug Administration has granted RadioGel Precision Radionuclide Therapy...
Vivos Inc. Provides 2021 Recap and Outlines 2022 Objectives
January 24, 2022 09:30 ET
|
Vivos Inc.
Richland WA, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), provides 2021 recap and outlines future objectives. Vivos’ CEO, Dr. Mike Korenko stated, “as we begin 2022, we wanted to...
Vivos Inc Announces Johns Hopkins University (Veterinary Clinical Trials Network) is a New Regional Clinic for Isopet®
November 23, 2021 09:30 ET
|
Vivos Inc.
This replaces and corrects the press release from November 22. Johns Hopkins (VCTN) Veterinary Clinical Trials Network is our teaming partner not the Center for Image Guided Animal Therapy (CIGAT). ...
Vivos Inc Signs a MOU for a New Regional Clinic in NY for IsoPet Therapy
October 18, 2021 09:30 ET
|
Vivos Inc.
Richland WA, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that it signed a Memorandum of Understanding with the Animal Hospital Surgical Center in East...
Vivos Inc Completes Certification Training Modules for Future IsoPet® Therapy Regional Clinics
September 22, 2021 09:30 ET
|
Vivos Inc.
Richland WA, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc working with FX Masse completed nine certification training modules that are part of the certification training...
Vivos Inc Initiates Isopet® Therapy in Horses
June 24, 2021 09:30 ET
|
Vivos Inc.
Richland WA, June 24, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) Vivos Inc announced that it has completed the first IsoPet® therapy on an equoid tumor. It was administered at the University...
Vivos Inc Completes Surrogate Lymph Node Testing Using Mouse Spleen Injections Demonstrating Uniform Perfusion and Stability
December 09, 2020 09:30 ET
|
Vivos Inc.
Richland WA, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce today that it worked with Mayo Clinic doctors to design and then conduct tests on the...
Vivos Inc Initiates IsoPet Therapy of Horses – Addressing Unmet Need for the Treatment of Equine Tumors
September 03, 2020 09:30 ET
|
Vivos Inc.
Richland WA, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce today that it is expanding Isopet® into the equine market by making IsoPet® available to...
Vivos Inc Provides Update on Initial Indication for Use for RadioGelTM Therapy
August 26, 2020 09:30 ET
|
Vivos Inc.
Richland WA, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), We are excited to announce that based on the recommendation of our Medical Advisory Board, Vivos Inc has decided on treating...
Vivos Inc Achieves Important Radiogel™ Development Milestones
June 24, 2020 07:30 ET
|
Vivos Inc.
Richland WA, June 24, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos announced today significant progress in its efforts to advance RadioGel™ for human therapy. Animal testing at the...